Susquehanna International Group, LLP Dia Medica Therapeutics Inc. Transaction History
Susquehanna International Group, LLP
- $568 Billion
- Q1 2024
A detailed history of Susquehanna International Group, LLP transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 209,332 shares of DMAC stock, worth $607,062. This represents 0.0% of its overall portfolio holdings.
Number of Shares
209,332
Previous 27,619
657.93%
Holding current value
$607,062
Previous $78,000
642.31%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding DMAC
# of Institutions
33Shares Held
3.85MCall Options Held
5.9KPut Options Held
1.4K-
Vanguard Group Inc Valley Forge, PA1.01MShares$2.94 Million0.0% of portfolio
-
First Manhattan CO New York, NY850KShares$2.47 Million0.01% of portfolio
-
Paragon Associates & Paragon Associates Ii Joint Venture Dallas, TX500KShares$1.45 Million2.47% of portfolio
-
Geode Capital Management, LLC Boston, MA239KShares$693,7810.0% of portfolio
-
Bleichroeder LP New York, NY222KShares$644,7190.19% of portfolio
About DiaMedica Therapeutics Inc.
- Ticker DMAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,443,100
- Market Cap $76.7M
- Description
- DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...